| Assessment Status | Rapid Review Complete |
| HTA ID | 21054 |
| Drug | Tirbanibulin |
| Brand | Klisyri® |
| Indication | For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2021 |
| Rapid review completed | 30/11/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tirbanibulin not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
